HIV Publications
| Tebas P, Bellos N, Lucasti C, Richmond G, Godofsky E, Patel I, Chiu YY, Evans C, Rowell L, Salgo M | |||
 |
 |
|
Enfuvirtide Does Not Require Dose Adjustment in Patients With Chronic Kidney Failure: Results of a Pharmacokinetic Study of Enfuvirtide in HIV 1 Infected Patients With Impaired Kidney Fucntion |
| J Acquir Immune Defic Syndr 2008 47(): 342 - 345 | |||
| Rockstroh J, Dejesus E, Donatacci L, Wat C, Bertasso A, Labriola-Tompkins E, Shikhman A, Atkins B, Guimaraes D, Wilkinson M, Thommes J, Rowell L, Demasi R, Salgo M | |||
|
|
|
Adherence to enfuvirtide and its impact on treatment efficacy |
| AIDS Res Hum Retroviruses. 2008 24(2): 141 - 148 | |||
| Reynes J, Arastéh K, Clotet B, Cohen C, Cooper DA, Delfraissy JF, Eron JJ, Henry K, Katlama C, Kuritzkes DR, Lalezari JP, Lange J, Lazzarin A, Montaner JS, Nelson M, O' Hearn M, Stellbrink HJ, Trottier B, Walmsley SL, Buss NE, Demasi R, Chung J, Donatacc | |||
|
|
|
Ninety-Six-Week Virologic and Immunologic Response and Safety Evaluation of Enfuvirtide with an Optimized Background of Antiretrovirals |
| AIDS Patient Care STDS 2007 21(81): 533 - 543 | |||
| Lalezari JP, Henry K, O'Hearn M, Montaner JS, Piliero PJ, Trottier B, Walmsley S, Cohen C, Kuritzkes DR, Eron JJ Jr, Chung J, DeMasi R, Donatacci L, Drobnes C, Delehanty J, Salgo M | |||
|
|
|
Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America |
| N Engl J Med. 2003 348(22): 2175 - 2185 | |||
| Lazzarin A, Clotet B, Cooper D, Reynes J, Arasteh K, Nelson M, Katlama C, Stellbrink HJ, Delfraissy JF, Lange J, Huson L, DeMasi R, Wat C, Delehanty J, Drobnes C, Salgo M | |||
|
|
|
Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 Europe and Australia |
| N Engl J Med. 2003 348(22): 2186 - 2195 | |||
